Laurence Reid, Director at Metagenomi Therapeutics, Inc. (MGX), bought 20,000 shares at $1.17 ($23K) on 2026-09-09, disclosed to the SEC on 2026-09-11.
Director Laurence Reid purchased 19,883 shares of Metagenomi Therapeutics for $23,263, marking the largest insider purchase in the company's history. This significant buy signals confidence in the stock's potential despite recent operational struggles.
The stock is trading at $1.16, down 4.92% over the last 30 days and 38.62% over the past year, placing it 70.63% below its 52-week high of $3.95.
Coming off a Q2 2026 earnings miss where revenue lagged estimates by 120.56% (Zacks, Aug 10, 2026), the next earnings report is a key catalyst. Additionally, the company reported a Q1 2026 loss with revenue missing estimates by 68.08% (Zacks, May 12, 2026), setting the stage for the next quarterly print.
The stock faces significant execution risk following a series of missed revenue estimates, including a 120.56% miss in Q2 2026 and a 68.08% miss in Q1 2026 (Zacks, Aug 10, 2026; May 12, 2026).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.17 | 19,883 | $23K | 99.4% |
| 2 | $1.18 | 117 | $138 | 0.6% |
| Total | $1.17 avg | 20,000 | $23K | 100% |
| Filing → |
| ALNY | SELL | 2014-08-20 | $909K | — | Filing → |
| ALNY | SELL | 2014-05-21 | $781K | — | Filing → |
| ALNY | SELL | 2014-02-20 | $1.6M | — | Filing → |